MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: Alliance Pharma drops as CEO departs, delays results again

ALN

Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines - Shares close down 14% in London on Wednesday, after Alliance Pharma says Chief Executive Officer Peter Butterfield has decided to leave the company ‘to pursue other business interests’. Following a ‘comprehensive’ search process, it appoints Nick Sedgwick as new CEO, starting on Monday next week. Sedgwick has 30 years experience in consumer health, Alliance Pharma says, most recently as regional director for UK & Ireland Consumer Health at Reckitt Benckiser Group PLC. Butterfield will remain with Alliance Pharma until June 30 to facilitate a ‘thorough’ handover, it says. Butterfield joined the board in 2010 and became CEO in 2018.

Alliance Pharma also notes that its 2023 results will not be published on Tuesday next week, as its audit continues. The company had already delayed its results twice, saying at the beginning and end of April that Deloitte LLP needs more time. It repeats that the details of its January trading update remain accurate.

Current stock price: 27.45 pence

12-month change: down 59%

Copyright 2024 Alliance News Ltd. All Rights Reserved.